• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CUTR

    Cutera Inc.

    Subscribe to $CUTR
    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cutera, Inc., a medical device company, engages in the research, development, manufacture, marketing, and servicing of laser and energy-based aesthetics systems for practitioners worldwide. The company offers truSculpt flex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; truSculpt for the non-surgical body sculpting market; Juliet, a laser for women's intimate health; Secret RF, a fractional radio frequency microneedling device for skin revitalization; and enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions and acne scars. It also provides excel HR platform, a hair removal solution for various skin types; excel V+, a vascular and benign pigmented lesion treatment platform; and xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity. In addition, the company offers GenesisPlus, CoolGlide, myQ, and skincare products. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills, cycle refills, consumable tips, and marketing brochures through the company's website cutera.com. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, and other qualified practitioners, as well as for physicians performing aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1988 and is headquartered in Brisbane, California.

    IPO Year: 2004

    Exchange: NASDAQ

    Website: cutera.com

    Recent Analyst Ratings for Cutera Inc.

    DatePrice TargetRatingAnalyst
    3/22/2024Underperform → Mkt Perform
    William Blair
    7/27/2023$14.00 → $18.00Underweight → Neutral
    Piper Sandler
    5/11/2023Outperform → Mkt Perform
    William Blair
    5/10/2023$14.00Underweight
    Piper Sandler
    3/30/2023Buy → Hold
    Maxim Group
    1/31/2023Mkt Perform
    William Blair
    1/11/2023$85.00 → $33.00Overweight → Neutral
    Cantor Fitzgerald
    12/28/2022$78.00 → $68.00Overweight
    Stephens
    10/14/2022$78.00Overweight
    Stephens
    11/4/2021$60.00Hold → Buy
    Maxim Group
    See more ratings

    Cutera Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cutera Inc.

      SC 13G/A - CUTERA INC (0001162461) (Subject)

      11/12/24 2:37:12 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cutera Inc.

      SC 13G/A - CUTERA INC (0001162461) (Subject)

      11/4/24 11:30:30 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cutera Inc.

      SC 13D/A - CUTERA INC (0001162461) (Subject)

      9/3/24 4:14:32 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cutera Inc.

      SC 13D/A - CUTERA INC (0001162461) (Subject)

      7/1/24 4:11:16 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D/A filed by Cutera Inc. (Amendment)

      SC 13D/A - CUTERA INC (0001162461) (Subject)

      5/22/24 3:57:46 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Cutera Inc. (Amendment)

      SC 13G/A - CUTERA INC (0001162461) (Subject)

      2/14/24 6:01:35 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Cutera Inc. (Amendment)

      SC 13G/A - CUTERA INC (0001162461) (Subject)

      2/13/24 5:02:40 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Cutera Inc. (Amendment)

      SC 13G/A - CUTERA INC (0001162461) (Subject)

      2/9/24 8:50:19 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Cutera Inc. (Amendment)

      SC 13G/A - CUTERA INC (0001162461) (Subject)

      2/6/24 4:20:03 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Cutera Inc.

      SC 13G - CUTERA INC (0001162461) (Subject)

      1/18/24 9:20:59 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Cutera Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer Patton Stephana Eilene covered exercise/tax liability with 623 shares, decreasing direct ownership by 0.80% to 77,216 units (SEC Form 4)

      4 - CUTERA INC (0001162461) (Issuer)

      2/21/25 1:43:37 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Harris Taylor C. covered exercise/tax liability with 4,620 shares, decreasing direct ownership by 2% to 255,744 units (SEC Form 4)

      4 - CUTERA INC (0001162461) (Issuer)

      2/21/25 1:42:45 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Wierbicki Paul

      3 - CUTERA INC (0001162461) (Issuer)

      2/19/25 4:04:44 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Interim CFO Drummond Stuart covered exercise/tax liability with 22 shares, decreasing direct ownership by 0.12% to 17,798 units (SEC Form 4)

      4 - CUTERA INC (0001162461) (Issuer)

      2/4/25 5:06:12 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Interim CFO Drummond Stuart covered exercise/tax liability with 69 shares and was granted 101 shares, increasing direct ownership by 0.18% to 17,820 units (SEC Form 4)

      4 - CUTERA INC (0001162461) (Issuer)

      1/3/25 4:29:28 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Interim CFO Drummond Stuart covered exercise/tax liability with 20 shares, decreasing direct ownership by 0.11% to 17,788 units (SEC Form 4)

      4 - CUTERA INC (0001162461) (Issuer)

      12/3/24 4:01:34 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Legal Officer Patton Stephana Eilene covered exercise/tax liability with 2,161 shares, decreasing direct ownership by 3% to 77,839 units (SEC Form 4)

      4 - CUTERA INC (0001162461) (Issuer)

      11/15/24 4:25:23 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Harris Taylor C. covered exercise/tax liability with 3,794 shares, decreasing direct ownership by 1% to 260,364 units (SEC Form 4)

      4 - CUTERA INC (0001162461) (Issuer)

      11/13/24 5:07:32 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Interim CFO Drummond Stuart covered exercise/tax liability with 19 shares, decreasing direct ownership by 0.11% to 17,808 units (SEC Form 4)

      4 - CUTERA INC (0001162461) (Issuer)

      11/5/24 4:19:32 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Hilleman Jeryl L

      4 - CUTERA INC (0001162461) (Issuer)

      11/5/24 4:17:08 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Cutera Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cutera upgraded by William Blair

      William Blair upgraded Cutera from Underperform to Mkt Perform

      3/22/24 7:28:54 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Cutera from Underweight to Neutral and set a new price target of $18.00 from $14.00 previously

      7/27/23 11:27:23 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera downgraded by William Blair

      William Blair downgraded Cutera from Outperform to Mkt Perform

      5/11/23 7:25:52 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Piper Sandler resumed coverage on Cutera with a new price target

      Piper Sandler resumed coverage of Cutera with a rating of Underweight and set a new price target of $14.00

      5/10/23 6:36:55 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera downgraded by Maxim Group

      Maxim Group downgraded Cutera from Buy to Hold

      3/30/23 9:15:54 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • William Blair initiated coverage on Cutera

      William Blair initiated coverage of Cutera with a rating of Mkt Perform

      1/31/23 9:03:56 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Cutera from Overweight to Neutral and set a new price target of $33.00 from $85.00 previously

      1/11/23 8:09:26 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stephens reiterated coverage on Cutera with a new price target

      Stephens reiterated coverage of Cutera with a rating of Overweight and set a new price target of $68.00 from $78.00 previously

      12/28/22 10:25:30 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stephens resumed coverage on Cutera with a new price target

      Stephens resumed coverage of Cutera with a rating of Overweight and set a new price target of $78.00

      10/14/22 7:17:28 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera upgraded by Maxim Group with a new price target

      Maxim Group upgraded Cutera from Hold to Buy and set a new price target of $60.00

      11/4/21 9:07:02 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Cutera Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cutera® Successfully Completes Restructuring Transaction and Moves Forward with Enhanced Capital Structure

      Emerges from Chapter 11 as a stronger company, well positioned for long-term growth Continuing to provide best-in-class aesthetic and dermatology solutions to customers CUTERA, INC., ("Cutera" or "the Company"), a leading provider of aesthetic and dermatology solutions, today announced that the Company has successfully completed its financial restructuring process and emerged from Chapter 11. Cutera emerges with a significantly stronger balance sheet, well positioned to drive innovation and growth. Through this process, Cutera has reduced its debt by nearly $400 million, or over 90%, and raised $65 million in new money financing from its existing lenders. "Today marks a significant mile

      5/1/25 5:20:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Announces Voluntarily Delisting from Nasdaq

      Cutera, Inc. ("Cutera" or the "Company") (NASDAQ:CUTR) today announced that it has formally notified The Nasdaq Stock Market LLC ("Nasdaq") of its intent to voluntarily delist its common stock from the Nasdaq Global Select Market. Cutera expects to file a Form 25 with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 20, 2025. The Company expects the delisting of the common stock to be effective on or about March 30, 2025. Following such delisting, the Company intends to file a Form 15 with the SEC to indefinitely suspend the Company's reporting obligations under the Securities Exchange Act of 1934, as amended. The s

      3/10/25 3:41:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Takes Steps to Strengthen Financial Foundation and Position the Company for Long-Term Success

      Enters into agreement to reduce debt by nearly $400 million and raise $65 million of new money from existing lenders Implementing pre-packaged financial restructuring plan with strong support of lenders, expected to emerge expeditiously within 60 days Continues to operate as usual and provide best-in-class aesthetic and dermatology solutions to customers CUTERA, INC., ("Cutera" or "the Company"), a leading provider of aesthetic and dermatology solutions, today announced that it is initiating a restructuring transaction with the support of a group of existing lenders, representing approximately 74% of the Company's notes, to strengthen its balance sheet and position Cutera for long-term s

      3/5/25 7:10:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® Announces Partnership with the Adaptive Training Foundation

      Cutera collaborates with Dr. Edward Alvarez to provide truFlex® muscle stimulation treatments to help enhance the strength and endurance of adaptive athletes CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announces their partnership with the Adaptive Training Foundation (ATF), a non-profit organization that provides access and inclusion to individuals living with physical or traumatic impairments empowering them through exercise and community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112062983/en/Cutera, Dr. Edward Alvarez, and the Adaptive Training team at the ATF facility in D

      11/12/24 8:00:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® Announces Third Quarter 2024 Financial Results

      CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the third quarter ended September 30, 2024. Consolidated revenue for the third quarter of 2024 of $32.5 million Cash, cash equivalents, and restricted cash of $59.0 million AviClear growth of 16% vs prior year period driven by international capital system sales Global core capital growth of 7% on a sequential quarterly basis Full-year guidance maintained for both revenue and year-end cash balance "Our third quarter reflects consistent execution against our strategic priorities, with core capital sales improving on a sequential basis, AviClear continuing to

      11/7/24 4:01:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® to Announce Third Quarter Results on November 7, 2024

      Cutera, Inc. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the third quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call at the following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remai

      10/7/24 6:48:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® Announces Second Quarter 2024 Financial Results

      CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2024. Consolidated revenue for the second quarter of 2024 of $34.4 million Cash, cash equivalents, and restricted cash of $84.3 million AviClear growth of 41% vs prior year period driven by international capital system sales Service growth of 7% vs prior year period, highlighting improvements in field service and overall customer support Completion of the Q4 2023 corporate restructuring program, and announcement of additional cost reduction initiatives, allowing for both improved cost structure and better organization al

      8/8/24 4:01:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® Announces Exclusive Distribution Agreement With L'Oréal® for SkinCeuticals® Products in Japan

      CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, and its Japanese subsidiary, Cutera KK, are pleased to announce a strategic partnership with L'Oréal Japan Co. to exclusively promote, market, sell and distribute select SkinCeuticals products to medical and physician-led clinics in Japan. "We are excited about this collaboration with L'Oréal Japan Co. to bring SkinCeuticals' renowned skincare innovations to aesthetic providers in Japan," said Brent Hauser, Cutera's International President. "This agreement underscores our commitment to supporting our existing customer base by expanding access to high-quality skincare solutions that meet the unique needs

      7/31/24 8:00:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® to Announce Second Quarter Results on August 8, 2024

      CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the second quarter ended June 30, 2024, after the market closes on Thursday, August 8, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call by following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remain open u

      7/26/24 11:53:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® Announces New Survey Data During Acne Awareness Month

      New insights reveal the profound impact of acne and the growing interest in modern treatments Cutera, Inc. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announces the release of important new acne survey data as part of June's Acne Awareness Month. The findings highlight the impact of acne on individuals and emphasize the substantial role of novel treatments like AviClear®, the first FDA-cleared energy-based device for the long-term treatment of mild, moderate, and severe inflammatory acne, in improving quality of life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613634097/en/(Graphic: Busines

      6/13/24 8:30:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Cutera Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Cutera® Appoints Jeryl L. Hilleman to Board of Directors

      Experienced Healthcare Executive Brings Extensive Financial and Operational Expertise to Cutera Board of Directors CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that Jeryl "Jeri" Hilleman will join its Board of Directors, effective July 12, 2024. Ms. Hilleman brings over 30 years of experience in the healthcare industry, with a proven track record in financial leadership, strategic planning, operational excellence, and corporate governance. Her extensive background in life sciences and medical technology, both as a public company CFO and as a corporate director, will be invaluable to Cutera as it continues to innovate, drive towar

      6/10/24 4:30:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Appoints Stephana Patton as Chief Legal Officer

      Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step

      11/13/23 8:30:00 AM ET
      $CUTR
      $EIGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Cutera, Inc. Appoints Brent Hauser as President, International

      Hauser Brings Over 20 Years of Aesthetics Industry Experience in Markets Across the Globe Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Brent Hauser as President, International, effective October 2, 2023. Mr. Hauser will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for commercial performance in existing international markets, expansion into new geographies, and the international launch of AviClear, the company's pioneering energy-based device for the treatment of mild to severe acne, in 2024. Mr. Hauser brings over 20 years of aest

      10/2/23 8:30:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera, Inc. Appoints Jeff Jones as Chief Operating Officer

      Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Jeff Jones as Chief Operating Officer, effective August 28, 2023. This move underscores Cutera's commitment to delivering world-class product quality, reliability, and service to customers. Mr. Jones will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for end-to-end operations, including manufacturing, quality, supply chain, field service engineering, and customer service. Jeff brings a wealth of experience, having spent 35 years in operational roles within the medical device industry, incl

      8/24/23 9:00:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera, Inc. Appoints Taylor Harris as Chief Executive Officer

      Follows Comprehensive Search Process; Brings Over 20 Years of Healthcare Industry Experience and Operational Expertise CUTERA, INC. ("Cutera" or the "Company") (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today announced that Taylor Harris has been appointed Chief Executive Officer, effective August 7, 2023. Mr. Harris will succeed Sheila Hopkins, who has been serving as Interim Chief Executive Officer since April 2023. Mr. Harris and Ms. Hopkins will both continue serving as members of Cutera's Board of Directors. Mr. Harris joined Cutera's Board in June 2023. He is a proven executive and brings over 20 years of operational expertise as well as healthcare a

      7/27/23 9:00:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SetPoint Medical Appoints Rohan Seth as Chief Financial Officer

      Accomplished finance leader joins SetPoint Medical as it advances its development of a novel neuroimmune modulation platform for rheumatoid arthritis SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced the appointment of Rohan Seth as Chief Financial Officer (CFO). "I am excited to welcome Rohan to the SetPoint leadership team," said Murthy Simhambhatla, Ph.D., President and CEO of SetPoint Medical. "Rohan's proven track record of success in managing finance and business development functions will be instrumental as we continue to advance our therapeutic platform through clinical development." "I am honored to j

      6/12/23 8:00:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Comments on Termination of Voce Capital's Special Meeting Proxy Solicitation

      Resolves Dispute with Former CEO David Mowry CUTERA, INC. ("Cutera" or the "Company") (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today commented on the termination of the proxy solicitation by Voce Capital Management LLC ("Voce Capital") with respect to the Special Meeting of Stockholders, scheduled for June 9, 2023 (the "Special Meeting"). Cutera issued the following statement: The Special Committee of the Cutera Board of Directors deeply values the constructive engagement we have had with our stockholders over recent weeks. The Board refreshment we announced on May 9, 2023, followed an agreement with two of our largest stockholders, which collectively

      5/12/23 9:00:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Directors J. Daniel Plants and David Mowry Respond to Special Committee's Attempt to Rewrite History

      Clarify What This Campaign is About and What it is Not Cite Recent Value-Destructive Actions of the Special Committee as Further Support for Reconstituting the Board Highlight Multiple False and Misleading Statements from the Special Committee Today J. Daniel Plants, Founder and Chief Investment Officer of Voce Capital Management LLC and a member of the Board of Directors (the "Board") of Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), and David Mowry, also a Cutera Director – who together own approximately 7.0% of the outstanding shares of Cutera – issued the following statement in response to a recent press release from the Special Committee of Cutera's Board: "The events

      4/18/23 4:15:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera, Inc. Announces Executive Leadership and Governance Changes

      Independent Board Member Sheila A. Hopkins Appointed Interim CEO; Search for Permanent CEO Underway Janet D. Widmann Appointed Independent Chair Executive Chairman Daniel Plants and CEO David Mowry Terminated for Cause Withdraws 2023 Outlook CUTERA, INC. (the "Company") (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today announced significant changes to the Company's executive leadership to focus on improving performance and results. The Board of Directors (the "Board") has appointed Sheila A. Hopkins as Interim Chief Executive Officer ("CEO") and Janet D. Widmann as Independent Chair of the Board, effective immediately. The Board's search for a permanent

      4/12/23 6:00:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Argo Group Announces Appointment of J. Daniel Plants to Board of Directors

      Mr. Plants will join Strategic Review and Human Resources Committees Argo Group International Holdings, Ltd. (NYSE:ARGO) ("Argo" or "the Company") today announced the August 4, 2022 appointment of J. Daniel Plants as an independent member of the Company's board of directors (the "Board"). Mr. Plants is a seasoned investor, financial executive and senior advisor with three decades of experience helping companies successfully navigate change and unlock shareholder value. He currently serves as Chief Investment Officer of Voce Capital Management LLC, which he founded in 2011 after working at several leading financial institutions, including in executive positions in the mergers and acquisiti

      8/8/22 4:59:00 PM ET
      $ARGO
      $CALX
      $CUTR
      Specialty Insurers
      Finance
      Telecommunications Equipment
      Consumer Discretionary

    Cutera Inc. SEC Filings

    See more
    • SEC Form EFFECT filed by Cutera Inc.

      EFFECT - CUTERA INC (0001162461) (Filer)

      3/26/25 12:15:06 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form POS AM filed by Cutera Inc.

      POS AM - CUTERA INC (0001162461) (Filer)

      3/25/25 6:30:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 25 filed by Cutera Inc.

      25 - CUTERA INC (0001162461) (Filer)

      3/20/25 12:48:01 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - CUTERA INC (0001162461) (Filer)

      3/10/25 3:21:05 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by Cutera Inc.

      S-8 POS - CUTERA INC (0001162461) (Filer)

      3/5/25 5:18:02 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by Cutera Inc.

      S-8 POS - CUTERA INC (0001162461) (Filer)

      3/5/25 5:17:52 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by Cutera Inc.

      S-8 POS - CUTERA INC (0001162461) (Filer)

      3/5/25 5:17:32 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by Cutera Inc.

      S-8 POS - CUTERA INC (0001162461) (Filer)

      3/5/25 5:17:43 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by Cutera Inc.

      S-8 POS - CUTERA INC (0001162461) (Filer)

      3/5/25 5:17:21 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by Cutera Inc.

      S-8 POS - CUTERA INC (0001162461) (Filer)

      3/5/25 5:17:11 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Cutera Inc. Financials

    Live finance-specific insights

    See more
    • Cutera® Announces Third Quarter 2024 Financial Results

      CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the third quarter ended September 30, 2024. Consolidated revenue for the third quarter of 2024 of $32.5 million Cash, cash equivalents, and restricted cash of $59.0 million AviClear growth of 16% vs prior year period driven by international capital system sales Global core capital growth of 7% on a sequential quarterly basis Full-year guidance maintained for both revenue and year-end cash balance "Our third quarter reflects consistent execution against our strategic priorities, with core capital sales improving on a sequential basis, AviClear continuing to

      11/7/24 4:01:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® to Announce Third Quarter Results on November 7, 2024

      Cutera, Inc. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the third quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call at the following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remai

      10/7/24 6:48:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® Announces Second Quarter 2024 Financial Results

      CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2024. Consolidated revenue for the second quarter of 2024 of $34.4 million Cash, cash equivalents, and restricted cash of $84.3 million AviClear growth of 41% vs prior year period driven by international capital system sales Service growth of 7% vs prior year period, highlighting improvements in field service and overall customer support Completion of the Q4 2023 corporate restructuring program, and announcement of additional cost reduction initiatives, allowing for both improved cost structure and better organization al

      8/8/24 4:01:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® to Announce Second Quarter Results on August 8, 2024

      CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the second quarter ended June 30, 2024, after the market closes on Thursday, August 8, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call by following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remain open u

      7/26/24 11:53:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Announces First Quarter 2024 Financial Results

      Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today reported financial results for the first quarter ended March 31, 2024. Consolidated revenue for the first quarter of 2024 of $38.8 million. Strong sequential increase in AviClear revenue, driven by a business model shift in North America and a successful initiation of the International limited commercial release, during the first quarter of 2024. Recent highlights include the launch of xeo+ and the inaugural session of Cutera Academy, focused on equipping customers with the tools to build successful AviClear practices. "I am pleased with our progress in the fi

      5/9/24 4:01:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera to Announce First Quarter Results on May 9, 2024

      Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 9, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m. ET) that same day. Participants can register for the conference call at the following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Re

      4/26/24 8:00:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Announces Fourth Quarter and Full-Year 2023 Financial Results Along with 2024 Outlook

      Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today reported financial results for the fourth quarter and full-year ended December 31, 2023. Consolidated revenue for the fourth quarter of 2023 of $49.5 million Full-year 2023 revenue of $212.4 million, ahead of guidance of approximately $205 million Cash and marketable securities of $143.6 million as of December 31, 2023, ahead of guidance of approximately $135 million Completion of corporate restructuring program, allowing for both an improved cost structure and better organizational alignment Successful execution of the North American limited commercial rel

      3/21/24 4:01:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera to Announce Fourth Quarter and Full-Year 2023 Results on March 21, 2024

      Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Thursday, March 21, 2024. The Company intends to file its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023 and restated Quarterly Reports for the first and second quarters of 2023 in the week beginning March 4, 2024. As previously reported, the delay in filing the Quarterly Reports was due to the identification of an inventory shortfall relative to the system of record. Due to the time-consuming nature of th

      3/1/24 8:30:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Provides Third Quarter 2023 Business Update

      Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today provided preliminary financial results for the third quarter ended September 30, 2023, as well as recent business updates. Some Company highlights: Consolidated revenue for the third quarter of 2023 of $46.5 million, a decrease of 26% compared to the third quarter of 2022 Cash and marketable securities of $179.5 million as of the end of the third quarter Announcement of an enhanced AviClear offering, including the option to purchase the device upfront with a corresponding reduction in treatment costs Initiation of a global restructuring program, expected to sa

      11/8/23 4:01:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera, Inc. to Announce Third Quarter Results on November 8, 2023

      Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the third quarter of 2023 after the market close on Wednesday, November 8, 2023. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m. ET) that same day. To join the conference call, dial 1-800-319-4610 (domestic) or +1-631-891-4304 (international) and ask to join Cutera's earnings conference call. The call will also be webcast and can be accessed from the Investor Relations section of Cutera's website at http://www.cutera.com/. The webcast repl

      10/25/23 8:06:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care